Evidence map›Paper›PMID 18035553›Full record

ReviewSeminars in immunology2007

Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection.

Lori L Hudson, M Louise Markert, Blythe H Devlin, Barton F Haynes, Gregory D Sempowski

7 registry-linked trialsAbstract readReview
In one paragraph

Review in Seminars in immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00566488 phase1completednot on this map

Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2005 to 2019Enrolled25ConditionsDiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge SyndromeArmsThymus/Parathyroid Transplantation
NCT00576407 phase2completednot on this map

Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan1991 to 2017Enrolled26ConditionsDiGeorge Syndrome, Complete Typical DiGeorge AnomalyArmsCultured Thymus Tissue for Implantation (CTTI)
NCT00576836 phase2completednot on this map

Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2004 to 2019Enrolled7ConditionsDiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation
NCT00579527 phase1 / phase2completednot on this map

Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2005 to 2017Enrolled14ConditionsDiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine
NCT00579709 phase1completednot on this map

Thymus Transplantation With Immunosuppression, #884

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2002 to 2019Enrolled15ConditionsDiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge SyndromeArmsThymus Tissue for Transplantation
NCT01220531 nacompletednot on this mapstarted 2010, after this paper: background citation

Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2010 to 2023Enrolled29ConditionsComplete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue
NCT02274662 phase4completednot on this mapstarted 2014, after this paper: background citation

Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2014 to 2023Enrolled11ConditionsPoor Thymic Function, Immunodeficiency, Athymia, ImmunoreconstitutionArmsCultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Organ-on-a-Chip for Cancer and Immune Organs Modeling.Advanced healthcare materials · 2019
    Review
  2. Review
  3. Observational
  4. Thymic rejuvenation and aging.Current opinion in immunology · 2013
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Cytokines, leptin, and stress-induced thymic atrophy.Journal of leukocyte biology · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lori L HudsonDuke University Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina 27710, USA.
M Louise Markert
Blythe H Devlin
Barton F Haynes
Gregory D Sempowski

Funding

Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Duke University Center for Translational ResearchP30AI051445 · NIAID · DUKE UNIVERSITY · PI FROTHINGHAM, RICHARD · 2002 to 2006
$8.1M
THYMIC TRANSPLANTATION IN COMPLETE DIGEORGE SYNDROMER01AI047040 · NIAID · DUKE UNIVERSITY · PI MARKERT, M. LOUISE · 1999 to 2014
$8.0M
Preclinical studies of unrelated cord blood transplantationP01HL067314 · NHLBI · DUKE UNIVERSITY · PI CHAO, NELSON J. · 2002 to 2005
$6.9M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
Dynamics of TCR Repertoire Following Thymus TransplantR01AI054843 · NIAID · DUKE UNIVERSITY · PI MARKERT, M. LOUISE · 2004 to 2008
$1.9M
Mechanisms of Age Induced Thymic AtrophyR01AG025150 · NIA · DUKE UNIVERSITY · PI SEMPOWSKI, GREGORY D · 2005 to 2009
$1.5M
Parathyroid and Thymus Transplants in DiGeorge SyndromeR21AI060967 · NIAID · DUKE UNIVERSITY · PI MARKERT, MARY LOUISE · 2004 to 2005
$396k
MECHANISMS OF T-LYMPHOCYTE DEVELOPMENTR01CA028936 · NCI · DUKE UNIVERSITY · PI HAYNES, BARTON F · 1985 to 2000
$286k
NCI NIH HHS R01-CA28936NCRR NIH HHS M03-RR30NHLBI NIH HHS P01 HL067314NHLBI NIH HHS P01-HL67314NIAID NIH HHS P30 AI051445NIAID NIH HHS P30-AI51445NIAID NIH HHS R01 AI047040NIAID NIH HHS R01 AI054843NIAID NIH HHS R01-AI47040NIAID NIH HHS R01-AI54843NIAID NIH HHS R21 AI060967NIAID NIH HHS R21-AI60967NIAID NIH HHS T30-AI52077NIAID NIH HHS T32 AI052077NIAID NIH HHS UC6 AI058607NIA NIH HHS R01 AG025150NIA NIH HHS R01-AG25150
6 · The paper itself

Abstract

The thymus is essential for proper development and maintenance of a broad T cell repertoire capable of recognizing a wide-range of foreign antigens. Recent advances in multicolor flow cytometry, non-invasive imaging techniques, and molecular assessments of thymic function have enabled a more comprehensive characterization of human thymic output in clinical settings than in the past. These techniques have been particularly valuable in monitoring human T cells after therapeutic thymic grafting for complete DiGeorge syndrome and during HIV-1 infection and AIDS. By defining the degree and mechanisms of T cell reconstitution in these settings, clinical investigators and primary caregivers have been able to better diagnose, treat and care for individuals with congenital or acquired immune deficiencies associated with loss of thymic function.

Indexed as

HIV-1Acquired Immunodeficiency SyndromeCD4 Lymphocyte CountDiGeorge SyndromeHumansInterleukin-2Receptors, Antigen, T-CellThymus GlandT-LymphocytesInterleukin-2Receptors, Antigen, T-Cell

Identifiers

PMID18035553
PMCPMC2189557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.